Catalent and Mitsubishi GC team up for Asian cell line offering

By Fiona BARRY contact

- Last updated on GMT

Catalent will market its cell lines to Asia.
Catalent will market its cell lines to Asia.

Related tags: Cell lines, Stem cell

Catalent is taking aim at the Asian market with a partnership with Mitsubishi Gas Chemical Company to make cell lines for the region.

The firms announced plans to jointly market Catalent’s GPEx, a vector for mammalian cell lines, for preclinical screening uses and as a CMO service producing finished biopharmaceuticals.

Catalent will engineer and develop the cell lines and Mitsubishi Gas Chemical Company (MGC)’s pharma wing will take over manufacturing for Phase III and commercial applications. The deal also allows MGC to use GPEx tech to make biosimilars cell lines for pharmaceutical partners for product development and commercialisation.

Using GPEx in the collaboration will speed the development and manufacturing of biologics for Asian customers faster than if they produce them within their own companies, said Catalent spokesman Chris Halling.

Catalent already has agreements to produce cell lines using GPEx for several biologics organisations in the Asia-Pacific region.

Last year it signed a deal to make mammalian cells for Chinese company Hisun Pharmaceuticals​ for the manufacture of infliximab, alemtuzumab and adalimumab biosimilars. It also makes anti-CORIN (the gene that encodes the atrial natriuretic peptide-converting enzyme) mAbs for the Centre for iPS Cell Research and Application at Japan’s Kyoto University, for work on induced pluripotent stem cell therapies.  

Catalent declined to comment on which Asian markets it plans to target except to say the company has facilities in Australia, Japan and Singapore, as well as two new facilities in China.

IP protections can be a fraught issue for contract development and manufacturing organisations moving into the region. Lonza told us in 2012​ it delayed launch of its GS Xceed expression system until it could resolve “the lack of IP coverage for that territory.​”

Lonza spokeswoman Melanie Disa went on to describe novel biopharmaceuticals and biosimilars as “a growing market in Asia, specifically, China, India and Korea.​”

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars